STRATEC SE: DR. RUDOLF EUGSTER AS NEW CHAIR OF SUPERVISORY BOARD / PLANNED INCREASE IN NUMBER OF SUPERVISORY BOARD MEMBERS

Birkenfeld, November 3, 2021

STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) can today announce that Dr. Rudolf Eugster has been appointed by Mannheim District Court to be a member of the Supervisory Board of STRATEC SE as of October 26, 2021. Furthermore, at its meeting today the Supervisory Board elected Dr. Rudolf Eugster as the new Chair of the Supervisory Board.

Given the various management positions he has held in companies with international operations, Dr. Rudolf Eugster has longstanding experience in strategic planning and in financial reporting and controlling. Among other roles, he was a member of the Board of Management at Tecan Group AG (SIX Swiss Exchange: TECN) from 2002 to 2020 and has in-depth knowledge of the STRATEC Group's target markets. Dr. Rudolf Eugster is a Swiss citizen and holds a degree in chemistry, a doctorate in technical sciences, and a postgraduate qualification in business administration, all of which obtained at the Swiss Federal Institute of Technology in Zurich (ETH Zürich), Switzerland.

The court appointed the new Supervisory Board member in response to a petition submitted by the Board of Management of STRATEC SE. This was necessitated by Prof. Dr. Stefanie Remmele standing down from her positions as a member and as the Chair of the Supervisory Board of STRATEC SE as of October 22, 2021 due to personal reasons.

Dr. Frank Hiller, Deputy Chair of the Supervisory Board of STRATEC SE: "We are delighted to have gained an extremely experienced manager in Dr. Rudolf Eugster, one who can look back on more than 20 years of activity as CFO. The company's management would also like to thank Prof. Dr. Stefanie Remmele for her constructive and competent work and for the contribution she made to the company's success over the past seven years, of which around one year as Chair of the Supervisory Board."

To account for external requirements and its own targets in terms of diversity, as well as to further widen the range of experience available on the board, the company also plans to request approval from the next Annual General Meeting for an increase in the number of Supervisory Board members from its present total of three to five.

ABOUT STRATEC
STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For its analyzer systems and consumables, STRATEC covers the entire value chain - from development to design and production through to quality assurance.

The partners market the systems, software, and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler | Investor Relations & Corporate Communications
Tel: +49 7082 7916-6515
ir@stratec.com
www.stratec.com